Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Devimistat by Cornerstone Pharmaceuticals for Metastatic Biliary Tract Cancer: Likelihood of Approval
Devimistat is under clinical development by Cornerstone Pharmaceuticals and currently in Phase II for Metastatic Biliary Tract Cancer. According to...
Data Insights
Devimistat by Cornerstone Pharmaceuticals for Sarcomas: Likelihood of Approval
Devimistat is under clinical development by Cornerstone Pharmaceuticals and currently in Phase I for Sarcomas. According to GlobalData, Phase I...